Metabolic Surgery for Type 2 Diabetes in Turkey — RYGB, Duodenal Switch & SADI-S at Eyeglow Istanbul
Metabolic surgery (gastric bypass, duodenal switch, SADI-S) for type 2 diabetes — IFSO-ADA 2016 criteria, BMI ≥30 with T2DM inadequately controlled on optimal medical therapy. RYGB achieves 30–60% complete T2DM remission at 5 years (STAMPEDE trial, NEJM 2017); DS/BPD-DS achieves 60–80%. Honest disclosure: relapse rates 25–35% at 10 years, mortality 0.1–0.3%, lifelong nutritional supplementation mandatory. Partner bariatric surgeon team at accredited Istanbul hospital.
Verified and listed across leading directories and authorities
What is metabolic surgery for type 2 diabetes?
Metabolic surgery refers to bariatric procedures — primarily Roux-en-Y Gastric Bypass (RYGB) and Duodenal Switch (DS/BPD-DS) — performed specifically for the metabolic indication of type 2 diabetes remission, in addition to or in place of the weight-loss indication. Per IFSO-ADA 2016 and ADA Standards of Care 2024, surgery is indicated for adults with BMI ≥30 and T2DM inadequately controlled despite optimal medical therapy. The STAMPEDE trial (NEJM 2017) demonstrated 29–30% complete T2DM remission (HbA1c <6.5% off medication) at 5 years for RYGB, versus 5% for intensive medical therapy alone. DS achieves 60–80% complete remission in registry data.
At Eyeglow Health, metabolic surgery is coordinated through our accredited partner bariatric surgeon team at an accredited hospital in Istanbul. Eyeglow Health is an eye-care specialist clinic — bariatric and metabolic surgical procedures are delivered by our partner team. This arrangement is disclosed transparently at every stage. Both Eyeglow and the partner hospital hold the Turkish Ministry of Health International Health Tourism Authority Certificate. We follow IFSO (International Federation for the Surgery of Obesity), ASMBS (American Society for Metabolic and Bariatric Surgery), and ADA (American Diabetes Association) guidelines for candidate selection, procedure recommendation, and post-operative metabolic monitoring.
Important honest context: metabolic surgery achieves remission, not a cure. Relapse rates of 25–35% within 10 years are documented in major trials. The decision to pursue metabolic surgery should be made after discussion with your endocrinologist, using your specific HbA1c history, diabetes duration, C-peptide result, and medication burden as inputs to the risk-benefit calculation — not from a web page alone.
From eligibility review to 12-month metabolic follow-up
- 01
Metabolic candidacy assessment — T2DM history, HbA1c, medication burden, beta-cell reserve
You share your T2DM diagnosis duration, current HbA1c, medications (oral antidiabetics, insulin type and dose), comorbidities (hypertension, dyslipidaemia, nephropathy, neuropathy, retinopathy), BMI, and C-peptide result if available. The bariatric surgeon reviews IFSO-ADA 2016 and ADA Standards of Care 2024 criteria — metabolic surgery is indicated for adults with BMI ≥30 and T2DM inadequately controlled despite optimal medical therapy. If your BMI is below 30 with T2DM, we discuss the evidence honestly — surgery below BMI 30 is not standard-of-care per current guidelines. Remission probability is higher with shorter diabetes duration (<5 years), preserved beta-cell function (C-peptide >1 ng/ml), and lower pre-op insulin requirement.
- 02
Endocrinology review + T2DM optimisation + pre-operative assessment
Full blood panel: HbA1c, fasting glucose, C-peptide, insulin level, full metabolic panel, liver and kidney function, lipid profile, TSH, vitamin D, B12, iron, zinc, selenium (critical for DS/BPD-DS baseline). Upper-GI endoscopy (exclude H. pylori — active infection treated before surgery), abdominal ultrasound, ECG, chest X-ray, anaesthesia review, pulmonary function for DS/BPD-DS candidates. Pre-operative T2DM management optimisation — medications may be adjusted or temporarily held per endocrinology guidance before surgery. Pre-op liver-shrinking diet 10–14 days (critical for laparoscopic access safety).
- 03
Procedure selection — RYGB vs DS/BPD-DS vs SADI-S vs Sleeve
Procedure is individualised. RYGB (Roux-en-Y Gastric Bypass) is the metabolic gold standard — higher remission rate than sleeve, lower nutritional risk than DS, well-established 30-year evidence base including STAMPEDE trial. DS/BPD-DS (Biliopancreatic Diversion with Duodenal Switch) offers the highest T2DM remission rates (60–80%) but the most significant nutritional deficiency risk — protein malnutrition and fat-soluble vitamin (A, D, E, K) deficiency lifelong, requiring rigorous supplementation and monitoring. SADI-S (Single-Anastomosis Duodeno-Ileostomy with Sleeve) is a simplified single-anastomosis DS variant — similar metabolic benefit with one fewer anastomosis, lower theoretical complication risk, but longer-term data less mature than RYGB. Sleeve is discussed for context — it achieves lower T2DM remission (~50%) than RYGB and is not the preferred procedure for the metabolic indication when other factors are equal.
- 04
Roux-en-Y Gastric Bypass — surgical steps (90–150 minutes)
Under general anaesthesia, the laparoscopic RYGB creates a small gastric pouch (~30 ml) from the proximal stomach, disconnected from the majority of the stomach. The small intestine is divided and rerouted in a Y-configuration: the Roux limb (alimentary limb, ~100–150 cm) is connected to the pouch; the biliopancreatic limb carries bile and digestive enzymes from the excluded stomach and proximal duodenum; both limbs join at the jejunojejunostomy (the point where food and enzymes mix). Result: restriction (small pouch) plus partial malabsorption (reduced nutrient absorption in bypassed segment) plus gut hormone enhancement (enhanced GLP-1, GIP, peptide YY signalling — this is the primary driver of T2DM remission, not just weight loss).
- 05
Duodenal Switch (DS/BPD-DS) — surgical steps (120–180 minutes)
DS creates a sleeve gastrectomy (removing 70–80% of the stomach), then performs a duodenoileostomy — the duodenum is divided 3–4 cm from the pylorus and reconnected to a distal segment of the ileum (common channel 100–150 cm). The biliopancreatic limb carries bile from the liver and excluded duodenum. The result is severe caloric and fat malabsorption combined with restriction. SADI-S simplifies this to one anastomosis (sleeve + single duodeno-ileostomy, 250–300 cm common channel) reducing operative complexity. DS has the highest T2DM remission and the highest weight loss potential of all bariatric procedures. It also has the highest long-term nutritional deficiency risk: protein-calorie malnutrition requires >60–80g protein daily, fat-soluble vitamins (A, D, E, K) must be supplemented in water-soluble form indefinitely, and calcium absorption is severely reduced. Annual comprehensive nutritional bloods are non-optional.
- 06
Hospital recovery — 7–10 days
RYGB: 3–5 nights at partner accredited hospital. Anastomotic leak testing (upper GI contrast study or intraoperative air test), progressive oral intake protocol (clear liquids → full liquids → purée stages beginning in hospital), IV proton-pump inhibitor and DVT prophylaxis. DS/BPD-DS/SADI-S: 5–7 nights. More intensive nutritional monitoring during recovery because malabsorption begins immediately post-op. Protein supplementation starts in hospital. Discharge occurs once oral fluid and purée tolerance is confirmed, pain is controlled, and no leak or bleeding signs. Return to hotel for 2–3 nights before flying home is standard.
- 07
12-month structured metabolic follow-up + endocrinology coordination
Glucose monitoring is managed through the first weeks — rapid T2DM improvement after RYGB means insulin and oral antidiabetic doses frequently need reduction within days to weeks post-op (hypoglycaemia risk is real if pre-op doses continue unchanged). Scheduled video reviews at 1, 3, 6 and 12 months: HbA1c, fasting glucose, medication status, nutritional bloods (monthly for DS in year 1, quarterly for RYGB), weight loss curve, and comorbidity resolution. Endocrinology liaison is coordinated where insulin or complex medication management requires it. Patients must understand: "remission" means HbA1c <6.5% off all T2DM medication — this does not mean the diabetes is cured permanently. Relapse rate is 25–35% within 10 years; ongoing metabolic monitoring is lifelong.
RYGB vs Duodenal Switch vs SADI-S vs Gastric Sleeve for T2DM
All four procedures achieve T2DM improvement, with meaningfully different remission rates, nutritional risk profiles, and long-term data maturity:
| Aspect | RYGB (Bypass) | DS / BPD-DS | SADI-S | Gastric Sleeve |
|---|---|---|---|---|
| Mechanism | Restriction + malabsorption + gut hormone (GLP-1/GIP) enhancement | Severe malabsorption + restriction (highest gut hormone effect) | Malabsorption + restriction — single anastomosis DS variant | Restriction + ghrelin reduction — limited metabolic pathway |
| T2DM complete remission (5-yr) | 30–60% (STAMPEDE trial) | 60–80% | 50–70% (emerging data) | ~40–55% |
| T2DM relapse at 10 years | 25–35% (STAMPEDE 5-yr data) | Lower long-term relapse vs RYGB in small studies | Data maturing | Higher relapse than RYGB |
| Excess weight loss (5y) | 70–80% | 75–85% | 70–80% | 60–70% |
| Nutritional deficiency risk | Moderate (iron, B12, calcium, vitamin D) | High — protein malnutrition + fat-soluble vitamins lifelong | High — similar to DS, slightly less than BPD-DS | Moderate (B12, iron, calcium, vitamin D) |
| GERD (reflux) effect | Improves — preferred for severe GERD | Variable — avoid if severe pre-op GERD | Variable | Often worsens pre-existing GERD |
| Mortality rate (30-day) | 0.1–0.3% (IFSO Global Registry) | 0.3–0.5% (higher complexity) | ~0.2% (emerging data) | 0.1–0.3% |
| Hospital stay | 3–5 nights | 5–7 nights | 4–6 nights | 3 nights |
Personalised pricing
Every treatment plan is priced individually after your consultation. Request a written, all-inclusive quote — clear, itemised, and with no obligation.
Request a written quoteWhat's included in your metabolic surgery package
Included in package
- Pre-operative endocrinology-aligned T2DM assessment + HbA1c, C-peptide, metabolic panel
- Full blood panel + upper-GI endoscopy + H. pylori screening and treatment if positive
- Bariatric surgeon consultation + IFSO-ADA eligibility review + informed consent
- Metabolic surgery at partner accredited hospital (RYGB, DS/BPD-DS, or SADI-S)
- General anaesthesia + intraoperative anastomosis integrity testing
- Hospital stay — 7–10 days private room (procedure-dependent)
- 5-star hotel — 2–3 nights post-discharge
- VIP airport transfers + hospital-hotel transfers
- Post-op contrast study (upper-GI) before discharge
- All post-op medications: PPI, DVT prophylaxis, analgesia, anti-emetics
- Immediate peri-operative diabetes medication adjustment protocol
- 1, 3, 6 and 12-month video follow-up + HbA1c + nutritional bloods interpretation
- Lifelong nutritional supplementation protocol and prescription guidance at discharge
- Multilingual bariatric coordinator — 24/7 throughout stay
- Complication insurance policy (Türkiye Ministry of Health certified, covers surgical complications including infection, retreatment, and emergency intervention up to package value)
Paid separately
Items below are not part of the medical package — your coordinator helps you arrange them at no markup.
- Flights to/from Istanbul
- Personal expenses and food after discharge
- Lifelong nutritional supplements (multivitamin, B12, calcium + vitamin D, iron, zinc, water-soluble fat-soluble vitamins for DS/SADI-S — prescribed at discharge and essential indefinitely)
- Ongoing endocrinology follow-up in your home country (recommended — we coordinate referral)
- Local-country dietitian support after the 12-month programme ends
- Plastic surgery for post-weight-loss skin laxity (quoted separately)
- Travel insurance (recommended — covers flight cancellation, baggage, non-surgical medical emergencies abroad; we coordinate referral if needed)
Are you a candidate for metabolic surgery for T2DM?
You may be a good candidate if
- Your BMI is ≥30 with type 2 diabetes inadequately controlled (HbA1c >7%) despite optimal medical therapy, per IFSO-ADA 2016 joint statement and ADA Standards of Care 2024.
- You have shorter T2DM duration (<5–10 years), preserved beta-cell function (C-peptide >1 ng/ml), and are not fully insulin-dependent — these factors are associated with higher remission probability.
- You understand that surgery may achieve T2DM remission (HbA1c <6.5% off medication) but is not guaranteed, and that relapse rates of 25–35% at 10 years are documented in major trials including STAMPEDE.
- You are willing to commit to lifelong nutritional supplementation (non-negotiable for DS/SADI-S; important for RYGB), structured follow-up including nutritional bloods, and endocrinology coordination.
- You have discussed the metabolic and bariatric surgical options with your diabetologist or endocrinologist, and metabolic surgery has been identified as a clinically appropriate next step.
Metabolic surgery is not indicated if
- Your BMI is below 30 with T2DM — surgery below BMI 30 is not current standard-of-care per IFSO-ADA guidelines; discuss GLP-1 agonist therapy (semaglutide, tirzepatide) with your endocrinologist.
- Your T2DM duration is >15 years with complete insulin dependence, very low C-peptide (minimal beta-cell reserve) — remission probability is low and risk-benefit ratio shifts toward medical management.
- You are unwilling or medically unable to commit to lifelong vitamin and mineral supplementation — this is non-negotiable for DS and SADI-S; skipping it leads to serious nutritional complications (protein malnutrition, vitamin A blindness, severe osteoporosis).
- You have uncontrolled active psychiatric condition, active substance use disorder, or severe eating disorder that would compromise peri-operative and post-operative management.
- You are pregnant, breastfeeding, or planning pregnancy within 12 months.
Disclaimer. Information on this page is consistent with IFSO-ADA 2016 Position Statement, ADA Standards of Care 2024 (Metabolic Surgery section), STAMPEDE trial published data (Schauer et al., NEJM 2017), and IFSO Global Registry outcomes. Remission rates, relapse rates, and mortality figures cited are from published peer-reviewed sources — not marketing claims. This is educational information for patients considering metabolic surgery — it is not a substitute for individualised assessment by a bariatric surgeon and endocrinologist.
Realistic outcomes — the risks that actually matter
Metabolic surgery carries meaningful risks alongside meaningful benefits. We present both honestly — the same way our partner bariatric surgeon presents them in consultation:
Anastomotic leak (1–3% RYGB; 2–4% DS)
An anastomotic leak — a breach at a surgically created connection — is the most serious post-operative complication of RYGB and DS. Per IFSO Global Registry data, leak rates for RYGB are approximately 1–3% and for DS approximately 2–4% (higher complexity of multiple anastomoses). Leaks typically present within days 1–7 post-operatively with fever, tachycardia, abdominal pain or unexplained shoulder pain. An upper-GI contrast study before discharge is standard. Management ranges from percutaneous drainage and endoscopic stenting to re-operation. Patients are briefed to recognise warning signs and contact the coordinator immediately — delayed response is the primary determinant of severity.
T2DM relapse (25–35% at 10 years)
Metabolic surgery for T2DM achieves remission — it does not cure the disease. STAMPEDE trial 5-year data (Schauer et al., NEJM 2017) demonstrated RYGB complete T2DM remission (HbA1c <6.5% off all medication) in 29% of patients at 5 years versus 5% for intensive medical therapy alone. Partial remission (HbA1c <7% with reduced medication) was higher. However, relapse rates of 25–35% within 10 years are documented across major prospective studies. Predictors of relapse include weight regain, longer pre-surgical diabetes duration, insulin dependence, and lower C-peptide. Patients who achieve remission must continue lifelong HbA1c monitoring because remission can reverse without symptoms. "Surgery cured my diabetes" is not a clinically accurate framing — "surgery achieved durable remission in the majority of patients" is honest.
Mortality (30-day): 0.1–0.3% (RYGB); 0.3–0.5% (DS)
Per IFSO Global Registry data, 30-day mortality after Roux-en-Y Gastric Bypass in IFSO member centres is 0.1–0.3%. For Duodenal Switch (BPD-DS), the rate is slightly higher at approximately 0.3–0.5%, reflecting the higher procedural complexity. SADI-S mortality data is emerging and expected to be similar to RYGB. These rates are comparable to cholecystectomy or appendectomy in the same age and comorbidity range. The mortality risk of untreated obesity-related diabetes, cardiovascular disease and progressive nephropathy over 10–20 years typically exceeds the surgical mortality rate — but this calculation is individualised and belongs to the bariatric surgeon's consultation, not a web page.
Nutritional deficiency — lifelong mandatory supplementation
RYGB: moderate nutritional risk. Vitamin B12, iron, calcium, and vitamin D are the primary deficiencies. Oral supplementation daily and annual bloodwork are non-optional. DS/BPD-DS and SADI-S: severe nutritional risk. Fat-soluble vitamins (A, D, E, K) require water-soluble form supplementation because fat absorption is severely reduced. Protein intake must exceed 60–80g daily — falling below causes muscle wasting and protein malnutrition. Calcium absorption is severely impaired — calcium citrate (not carbonate) plus vitamin D is required. Zinc and selenium deficiency are specifically associated with DS. Annual comprehensive nutritional panel (25-OH vitamin D, A, E, K, zinc, selenium, protein, albumin, ferritin, B12, INR for vitamin K) is mandatory. Non-compliance with supplementation after DS leads to documented cases of blindness (vitamin A), severe osteoporosis (calcium/vitamin D), and severe neurological damage (B12, thiamine).
Dumping syndrome (RYGB-specific)
Early dumping syndrome affects 10–20% of RYGB patients: rapid gastric emptying of high-sugar or high-fat foods into the small intestine causes a sudden glucose surge and subsequent insulin over-response, producing palpitations, sweating, diarrhoea and lightheadedness 15–30 minutes after eating (early dumping) or 1–3 hours after eating (late dumping, from reactive hypoglycaemia). This is managed by eating slowly, avoiding high-sugar and high-fat foods, and separating solids from liquids. Most patients adapt within 6–12 months. Severe refractory dumping requires dietary review and occasionally medication. DS does not produce dumping syndrome in the same way due to different anatomy.
Marginal ulcer (RYGB-specific, 1–3%)
A marginal ulcer forms at the gastrojejunal anastomosis — the junction between the gastric pouch and the Roux limb. Incidence is approximately 1–3%. Risk factors: NSAID use (absolutely contraindicated after RYGB), smoking (vasoconstrictive effect on the anastomosis), H. pylori (treated pre-operatively), and proton-pump inhibitor non-compliance. Proton-pump inhibitor is prescribed for at least 6 months post-op and many patients continue indefinitely. Symptoms include epigastric pain, haematemesis. Managed with PPI intensification; severe cases require endoscopic or surgical intervention.